1 |
M.L. Martins, M.A. Pierossi, L.A. Moraes, W. Ribeiro, E.Abbib Jr., G.B. Mendes, A. Poli, G. De Nucci and M.N.Muscara, Comparative bioavailability of two atenolol tablet formulations in healthy male volunteers after a single dose administration, Int. J. Clin. Pharmacol Ther., 35, 324-328 (1997)
|
2 |
K.K. Peh, K.H. Yuen, J.W. Wong and W.T. Toh,Comparative bioavailability study of two atenolol table tpreparations, Drug Dev. Ind. Pharm., 25, 357-360 (1999)
DOI
ScienceOn
|
3 |
A.M. Barrett, J. Carter, J.D. Fitzgerald, R. Hull and D.Count, A new type of cardioselective adrenoceptive blocking drug, Br. J. Pharmacol, 48, 340 (1973)
|
4 |
J.D. Harry, M.F. Knapp and R.J. Linden, Proceedings: Antagonism by ICI 66082 of the effects of electrical stimulation on the right ansa subclavia of the dog, Br. J.Pharmacol., 51, 169 (1974)
DOI
ScienceOn
|
5 |
W.H. Frishman, Atenolol and timolol, two new systemic -adrenoceptor antagonists, N. Engl J. Med., 306, 1424-1462 (1982)
DOI
ScienceOn
|
6 |
H. Winkler, W. Ried and B. Lemmer, High-perfomance liquid chromatographic method for the quantitative analysis of the aryloxypropanolamines propranolol, metoprolol and atenolol in plasma and tissue, J. Chromatogr., 228, 223-234 (1982)
DOI
ScienceOn
|
7 |
R.C. Heel, R.N. Brogden, T.M. Speight and G.S. Avery,Atenolol: a review of its pharmacological properties and therapeutic effcacy in angina pectoris and hypertension, Drugs, 17, 425-460 (1979)
DOI
ScienceOn
|
8 |
식품의약품안전청 고시 제 2001-57호, 생물학적 동등성 시험기준 (2001. 9. 5)
|
9 |
K. Stoschitzky, G. Egginger, G. Zemig, W. Klein and W.Lindner, Stereoselective features of (R)- and (S)-atenolol: clinical pharmacological, Pharmacokinetic and radioligand binding studies, Chirality, 5, 15-19 (1993)
DOI
ScienceOn
|